Ken Griffin Axogen, Inc. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Axogen, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 25,700 shares of AXGN stock, worth $349,777. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,700
Previous 40,100
35.91%
Holding current value
$349,777
Previous $290,000
24.14%
% of portfolio
0.0%
Previous 0.0%
Shares
28 transactions
Others Institutions Holding AXGN
# of Institutions
163Shares Held
36.6MCall Options Held
230KPut Options Held
400-
First Light Asset Management, LLC Edina, MN4.09MShares$55.7 Million5.0% of portfolio
-
Black Rock Inc. New York, NY3.25MShares$44.2 Million0.0% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT3.01MShares$40.9 Million3.58% of portfolio
-
Morgan Stanley New York, NY2.9MShares$39.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.43MShares$33 Million0.0% of portfolio
About Axogen, Inc.
- Ticker AXGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 42,283,700
- Market Cap $575M
- Description
- AxoGen, Inc., together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgic...